The Premature Ejaculation drugs in development market research report provides comprehensive information on the therapeutics under development for Premature Ejaculation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Premature Ejaculation. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Premature Ejaculation by eight companies/universities/institutes. The top development phase for Premature Ejaculation is phase i with three drugs in that stage. The Premature Ejaculation pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Premature Ejaculation pipeline products market are: China Pharmaceutical University, Ctcbio and Plethora Solutions.
The key targets in the Premature Ejaculation pipeline products market include cGMP Specific 3′,5′ Cyclic Phosphodiesterase (cGMP Binding cGMP Specific Phosphodiesterase or PDE5 or PDE5A or EC 3.1.4.35), Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4), and Voltage Gated Sodium Channel (SCN).
The key mechanisms of action in the Premature Ejaculation pipeline product include Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4) Inhibitor with two drugs in Phase I. The Premature Ejaculation pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Premature Ejaculation pipeline products market including Small Molecule.
Premature Ejaculation overview
Premature ejaculation (PE), also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress, and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.
For a complete picture of Premature Ejaculation’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
